Congress demands documents from FDA on controversial approval of Biogen’s Alzheimer’s drug
WASHINGTON — Lawmakers have requested data and documents from the Food and Drug Administration related to the agency’s controversial accelerated approval of Biogen’s new Alzheimer’s drug Aduhelm.
Two prominent House Committees sent the request to Acting FDA Commissioner Janet Woodcock on Wednesday. The same panels have already requested documents from Biogen, but this is the first public request by congressional investigators directly to the agency.
